Table 2.
Summary of the frequencies of favorable and unfavorable GSTM1 and CYP1A1 genotypes in the study populations
| Groups | GSTM1 genotypesa (%) | CYP1A1 genotypes (%) | Combined GSTM1/CYP1A1 genotypes (%) | Total | |||||
|---|---|---|---|---|---|---|---|---|---|
| GSTM1(+) | GSTM1(-) | CYP1A1*2 non-carriers | CYP1A1*2 carriers | GSTM1(+) CYP1A1*2 non-carriers | GSTM1(-) CYP1A1*2 non-carriers | GSTM1(+) CYP1A1*2 carriers | GSTM1(-) CYP1A1*2 carriers | ||
| ED | 137 (55.7) | 109 (44.3) | 196 (79.7) | 50 (20.3) | 106 (43.1) | 90 (36.6) | 31 (12.6) | 19 (7.7) | 246 (100) |
| HD | 94 (46.1) | 110 (53.9) | 161 (78.9) | 43 (21.1) | 77 (37.7) | 84 (41.2) | 17 (8.3) | 26 (12.7) | 204 (100) |
| All LC patients | 67 (47.5) | 74 (52.5) | 104 (73.8) | 37 (26.2) | 49 (34.8) | 55 (39.0) | 18 (12.8) | 19 (13.5) | 141 (100) |
| SCC LC patients | 31 (44.3) | 39 (55.7) | 45 (64.3) | 25 (35.7) | 20 (28.6) | 25 (35.7) | 11 (15.7) | 14 (20.0) | 70 (100) |
| Non-SCC LC patients | 36 (50.7) | 35 (49.3) | 59 (83.1) | 12 (16.9) | 29 (40.9) | 30 (42.3) | 7 (9.9) | 5 (7.0) | 71 (100) |
aGSTM1 genotypes are designated as GSTM1(-) for the null and GSTM1(+) for the non-null